Expert Perspectives
Outbound Case Studies
What cognitive misunderstandings should Chinese enterprises avoid when going global to Nigeria? | Global Pioneers
Opportunities and challenges of the largest economy in West Africa
2025-12-29
"Discussing Compliance and Promoting Steady Overseas Expansion" - The Provincial Overseas Investment Legal Compliance and Outstanding Investment Case
Discuss compliance paths together and seek a future of development jointly
2025-12-29
How can the third-largest biometric technology company after fingerprint and facial recognition break through the overseas market monopolized by gian
Focusing on the second-generation biometric technology, "Magneton Technology" has broken into the Asian market with high-cost-performance products.
2025-12-22
One Chart to Analyze the 2025 "Country Trade Guide" | Report Interpretation
Accurately seize opportunities in Southeast Asia and avoid hidden reefs when going global.
2025-12-08
The situation in Brazil is too complicated. | Overseas Insights
When doing business in Brazil, being fast means being slow, and being slow means being fast.
2025-11-24
Actual Records of Pitfalls Encountered by Agents Going Global | Global Insights for Overseas Expansion
Going global with AI is like flying a plane while repairing it.
2025-11-24
Exclusive Interview with Huizhi | Under the Strong Supervision of Cross - border Compliance, How Can Overseas - going Enterprises Build the Optimal F
Reasonably reducing the tax burden cost is the fundamental purpose of tax compliance design.
2025-11-03
Why does Tmall choose Lazada as its first stop when its brands expand into Southeast Asia?
The olive branch extended by Southeast Asian local platforms to Tmall brands.
2025-10-21
How can Chinese B2B enterprises build brand narratives when going global?
Marketing transformation of Chinese enterprises going global: from price competition to brand trust, LinkedIn becomes a key platform.
2025-10-21
Innovative drugs go global, and milestone payments are gradually entering the harvest period.
Tidu Highlights: In the context where high return rates and low milestone payments are the norm in the BD of innovative drugs in China, achieving milestones has never been an easy task.
2025-10-21
10items per page
Jump toPage